https://vital.seals.ac.za/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://vital.seals.ac.za/vital/access/manager/Repository/vital:20497 Wed 12 May 2021 23:45:03 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:10152 Wed 12 May 2021 22:25:34 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:10157 Wed 12 May 2021 19:28:44 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:32341 Wed 12 May 2021 19:18:31 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:4406 0.9990) was attained for most analytes. The limits of detection and quantification ranged from 0.03 - 0.84 μg/ml and 0.81 - 1.89 μg/ml respectively for analytes in biological samples. LODs and LOQs for analytes in food and environmental samples ranged from 0.02 to 0.39 and 0.25 to 1.30 ng/g respectively.]]> Wed 12 May 2021 17:31:55 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:3862 Wed 12 May 2021 16:47:29 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:21223 Thu 13 May 2021 13:55:44 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:10153 Thu 13 May 2021 07:09:28 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:11023 Thu 13 May 2021 07:07:36 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:10155 Thu 13 May 2021 05:05:04 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:33938 Thu 13 May 2021 01:39:13 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:4456 Thu 13 May 2021 00:57:32 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:59929 Thu 08 Dec 2022 11:38:02 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:27018 Fri 15 Mar 2024 12:32:30 SAST ]]> https://vital.seals.ac.za/vital/access/manager/Repository/vital:37087 1, antagonism, respectively. Most combination treatments showed to have an antagonistic effect except for cisplatin:BC-7 (1:3, 1:1, 2:1, 3:1) and cisplatin:A. afra (1:3, 1:2, 1:1, 3:1) combinations that showed synergism. The 1:2 ratio of cisplatin:BC-7 and the 2:1 ratio of cisplatin:A. afra were additive. CI values were also calculated at inhibition of 10, 25 and 75% of HeLa cell growth, for each combination mixture. Antagonistic effects were frequently observed at lower effect levels such as at 10 and 25% inhibition of growth. However, this was not seen for the cisplatin:BC-7 combinations as all the ratios indicated synergism. Some of these ratios, such as the 1:3 and 1:2, even led to a greater degree of synergism being obtained, with noticeable antagonistic effects seen at 50 and 75% inhibition of growth. The current finding is that BC-7 and A. afra could lower the dose of cisplatin in combination to achieve a similar anti-cancer efficacy compared to the higher cisplatin dose when used alone. The lower dosage in combination could result in reduced drug resistance as well as limit the toxicity on normal cells associated with cisplatin treatment. In conclusion, this study shows, for the first time, that A. nemorosa has the potential to induce apoptosis and also has some anti- and pro-inflammatory activity in HeLa cancer cells. This study also enhanced the knowledge of the mechanism of apoptosis induction of BC-7, in a more detailed manner, as well as investigated its inflammatory effects for the first time. Results obtained for A. afra correlated nicely to previously reported studies and confirmed that the methods used in this study, although different, leads to the same conclusions. Combination treatments also indicated, for the first time, that BC-7 and A. afra have the ability to function in a synergic manner with cisplatin and proves that, although extensive research may have been done on a plant or compound, more can be discovered. This new information can lead to identification of new compounds in the plants and the integration of signalling pathways that can be targeted for treatment of cancer.]]> Fri 15 Mar 2024 11:56:53 SAST ]]>